Kezar Life Sciences, Inc.

Informe acción NasdaqCM:KZR

Capitalización de mercado: US$53.9m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Kezar Life Sciences Dirección

Dirección controles de criterios 2/4

El CEO de Kezar Life Sciences es Chris Kirk , nombrado en Nov 2023, tiene una permanencia de 2.5 años. compensación anual total es $1.22M, compuesta por 50.6% salario y 49.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.58% de las acciones de la empresa, por valor de $314.45K. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 9 años, respectivamente.

Información clave

Chris Kirk

Chief Executive Officer (CEO)

US$1.2m

Compensación total

Porcentaje del salario del CEO50.62%
Permanencia del CEO2.5yrs
Participación del CEO0.6%
Permanencia media de la dirección2.5yrs
Promedio de permanencia en la Junta Directiva9yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • Dec 08

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Oct 03

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Clinical-stage biotech Kezar Life Sciences (NASDAQ:KZR) on Monday said its investigational new drug application for its inhibitor zetomipzomib for the treatment of autoimmune hepatitis (AIH) had been cleared by the U.S. FDA. AIH occurs when the body's immune system attacks the liver, leading to chronic inflammation and damage to liver cells. KZR is evaluating zetomipzomib in a phase 2a clinical trial for the treatment of AIH patients who have not responded to standard of care treatment or have relapsed. The trial aims to enroll 24 patients, and the main goal of the study is the complete response rate, KZR said in a statement. KZR stock +1.3% to $8.90 after hours.
Artículo de análisis • Aug 15

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Aug 11

Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02

Kezar Life Sciences press release (NASDAQ:KZR): Q2 GAAP EPS of -$0.25 beats by $0.02. Cash, cash equivalents and marketable securities totaled $306.8 million.
Seeking Alpha • Jul 27

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Recent clinical trial momentum has started to inflect positive on the chart for Kezar Life Sciences. The stock has caught a bid in June whilst reducing equity beta to the broad sector, illustrating the sensitivity of its idiosyncratic risk premia. We've also identified a potential mispricing opportunity with a ~38% value gap to the upside, valuing KZR at $13. With this comes an opportunity to harvest alpha over the coming 4-month period into November. These and more points are discussed in this report. Investment summary Recent clinical trial momentum has begun to come through on the chart for Kezar Life Sciences, Inc. (KZR). Following regulatory updates in late June the stock has caught a bid and has our attention as a life sciences play to capture near to medium-term alpha. Here we've identified a potential mispricing to the upside and see a price objective of $13 for KZR over the coming 3-months. We feel the stock will continue breaking away from peers in the sector as investors reward its clinical trial momentum. We estimate the alpha opportunity to last until November, following Q3 earnings. With the view investors will continue to award idiosyncratic risk premia like positive trial readouts in FY22, we rate KZR a buy PT $13. Exhibit 1. KZR 9-month price action Data: Refinitiv Market factors are supportive of further upside We've observed a sharp pullback in growth factors and equity beta this year as investors look to step up in quality. As such, low-beta, high quality plays are optimal for budgeting equity risk in FY22. On that note, we observe two key findings from KZR's investment debate. Firstly, it has strengthened against the benchmark since June, after it first was punished early in that month from a setback in its PRESIDIO Phase 2 trial. Prior to this, it had been strengthening since November 2021. Following its most recent updates, discussed later, the KZR has caught a bid and is now performing against the SPX. Perhaps more importantly, however, is that its covariance structure has been shifting downwards since April and therefore looks to offer investors a source of uncorrelated alpha. Investors are paying a premium for idiosyncratic risk premia in FY22 and the fact KZR is bifurcating away from the broad market to the upside is evidence investors recognize this in the name, by estimation. Exhibit 2. Downshifting covariance structure whilst strengthening against benchmark is a bullish divergence factor Data: Updata Further evidence of this point is seen in the chart below. Firstly, the medical devices and health care equipment sector has also been curling up in H2 FY22. As observed, KZR is strengthening against an already performing sector, a clear differentiating factor. We also observe this isn't just sector beta, given the fact it has reduced correlation to the sector whilst gaining in relative strength, as seen below. Therefore, we believe this to be evidence of the market's rewarding of KZR's idiosyncratic risk premia that is now on offer. Exhibit 3. Further evidence of key differentials at work for KZR with investors outsizing the name versus the sector Data: Updata Regulatory tailwinds In late June, the company posted a set of positive updates from its clinical trial investigating zetomipzomib. It first announced that the MISSION open label Phase 2 trial, investigating zetomipzomib's use as an experimental therapy active lupus nephritis ("ALN"), showed a clinically meaningful response. ALN is a sub-condition of systemic lupus erythematosus ("SLE"), an autoimmune disorder that results in chronic inflammation of the body's connective tissue. It is estimated that ~50% of SLE patients are at risk of developing end-state renal disease that often leads to death. At present, the current standard of treatment is chronic non-steroidal anti-inflammatory ("NSAID") use, dialysis or full kidney transplantation ("FKE"). Zetomipzomib is indicated in usage here as is an immunoproteasome-selective inhibitor identified based on the optimization of ONX-0914. It shows a comparable cytokine inhibition profile peripheral blood mononuclear cells ("PBMC"). For the MISSION trial, the 21-patient cohort was dosed with 60mg of the compound via subcutaneous route 1x weekly as a combination therapy for 24 weeks. Of the group, 17 progressed through the trial, with 65% (11 out of17) of these achieving a ≥50% reduction in urine protein creatinine ratio ("UPCR") compared to baseline. Being a phase 2 trial, investigating safety and efficacy, the treatment was well tolerated with only 2 patients exhibiting serious adverse events. As an add-on, findings also showed that patients in also experienced reductions in extra-renal manifestations of SLE. One of the key benefits the label offers is that it offers an alternative to NSAID's, often the standard of care in SLE management. Long-term NSAID usage is linked to various medical conditions including Cushing's syndrome, peptic ulcers, acute renal failure and cardiovascular issues. Marcum and Hanlon (2010) illustrated that health care providers are often at risk of overprescribing NSAIDs as well. Hence, zetomipzomib has the potential to compete on top of the standard of care as a standalone drug class operating in its own segment. Price action responsive After de-rating substantially in H1 FY22, price action has now turned bullish following this most recent round of updates. In the days after the announcement, the KZR share price rallied over 100% as investors sought to price in the news. Upside has continued and based on the most recent price action we see a cluster of price targets towards $21.70, as seen on Exhibit 4. Shares are testing the first of several inner resistance lines and if it punches up above these this will be bullish confirmation towards our price target. Exhibit 4. Multiple upside targets to $21.70 Data: Updata On a 6-month daily cloud chart, shares have broken back into the cloud and are now trading within cloud support. The lag line is now testing the cloud and we await for this to breakout in order for full conviction on the upward trend. On balance volume has ticked north and suggests long-term volume is still gaining, whilst momentum still remains high as seen below. Exhibit 5. Trading into cloud support Data: Updata Tracing the fibs down from the March high to its May bottom we see the share has already retraced ~38% of the move, where it is currently being tested. We are looking for a bounce from this level to the 50% tab on the fib and this is at ~$11.40. Hence, we look for our next technical objective to be $11.40 from here. Exhibit 6. Data: Updata Valuation With its lack of profitability, assigning a concrete value for KZR is difficult. This is best done through a substantiative DCF, however, given the shifting rates regime and changing capital environment, the predictability of future cash flows is far less certain. However, KZR trades on ~3x book value, below the GICS sector median, as seen below. Exhibit 7. Multiples and comps Data: HB Insights At ~3x book value we would theoretically 'pay' $15, in other words we'd overpay by ~58.5%. We therefore believe KZR could presently be overvalued by that amount, and consequently price at $5.98 apiece, suggesting long-term valuations may already be reflective of the regulatory tailwinds discussed in this report.
Seeking Alpha • Jul 11

Kezar Life Sciences appoints Nick Mordwinkin as chief business officer

Kezar Life Sciences (NASDAQ:KZR) has announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as Chief Business Officer. Dr. Mordwinkin will be key to the next stage of Kezar’s growth and will be responsible for shaping the company’s business development strategy. Most recently, he served as Head of Corporate Development, Inflammation and Fibrosis, at Gilead Sciences.
Artículo de análisis • Jan 03

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Aug 26

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Apr 05

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Artículo de análisis • Mar 01

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

If you want to know who really controls Kezar Life Sciences, Inc. ( NASDAQ:KZR ), then you'll have to look at the...
Artículo de análisis • Jan 25

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Artículo de análisis • Dec 21

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Kirk en comparación con los beneficios de Kezar Life Sciences?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$45m

Dec 31 2025US$1mUS$618k

-US$56m

Sep 30 2025n/an/a

-US$62m

Jun 30 2025n/an/a

-US$71m

Mar 31 2025n/an/a

-US$79m

Dec 31 2024US$927kUS$600k

-US$84m

Sep 30 2024n/an/a

-US$96m

Jun 30 2024n/an/a

-US$99m

Mar 31 2024n/an/a

-US$101m

Dec 31 2023US$3mUS$242k

-US$102m

Sep 30 2023n/an/a

-US$88m

Jun 30 2023n/an/a

-US$83m

Mar 31 2023n/an/a

-US$74m

Dec 31 2022US$2mUS$468k

-US$68m

Sep 30 2022n/an/a

-US$64m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$58m

Dec 31 2021US$2mUS$443k

-US$55m

Sep 30 2021n/an/a

-US$51m

Jun 30 2021n/an/a

-US$48m

Mar 31 2021n/an/a

-US$45m

Dec 31 2020US$880kUS$426k

-US$42m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$37m

Dec 31 2019US$2mUS$410k

-US$35m

Compensación vs. Mercado: La compensación total de Chris($USD1.22M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD658.93K).

Compensación vs. Ingresos: La compensación de Chris ha aumentado mientras la empresa no es rentable.

CEO

Chris Kirk (53 yo)

2.5yrs
Permanencia
US$1,220,828
Compensación

Dr. Christopher J. Kirk, also known as Chris, Ph.D. is a Director of Juvena Therapeutics, Inc. He serves as Member of Scientific Advisory Board at Rain Oncology Inc. (formerly known as Rain Therapeutics In...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Christopher Kirk
Co-Founder2.5yrsUS$1.22m0.58%
$ 314.4k
John Fowler
Co-Founder & Directorno dataUS$76.83k0.59%
$ 317.9k
Marc Belsky
CFO & Secretary8.2yrsUS$610.12k0.025%
$ 13.6k
Mark Schiller
Chief Operations Officerless than a yearUS$603.82k0.037%
$ 20.0k
Jack Taunton
Co-Founderno datasin datossin datos
Pichi Chiang
Senior Vice President & Controllerno datasin datos0.037%
$ 19.8k
2.5yrs
Permanencia media
53yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de KZR se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Christopher Kirk
Co-Founder11.3yrsUS$1.22m0.58%
$ 314.4k
John Fowler
Co-Founder & Director11.3yrsUS$76.83k0.59%
$ 317.9k
Michael Kauffman
Independent Director9.4yrsUS$75.77k0.086%
$ 46.4k
Franklin Berger
Independent Director10.3yrsUS$71.27k0.79%
$ 427.3k
Graham Cooper
Independent Chairman8.6yrsUS$105.77k0%
$ 0
Elizabeth Ijeoma Garner
Independent Director6.4yrsUS$73.27k0%
$ 0
Courtney Wallace
Independent Director4.4yrsUS$64.77k0%
$ 0
Micki Klearman
Independent Director4.9yrsUS$69.77k0%
$ 0
9.0yrs
Permanencia media
56yo
Promedio de edad

Junta con experiencia: La junta directiva de KZR se considera experimentada (9 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/13 14:51
Precio de las acciones al final del día2026/05/08 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Kezar Life Sciences, Inc. está cubierta por 4 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Maurice RaycroftJefferies LLC
Philip NadeauTD Cowen
Derek ArchilaWells Fargo Securities, LLC